INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $468,543 | +48.4% | 25,272 | -11.5% | 0.28% | +52.4% |
| Q2 2023 | $315,652 | +14.0% | 28,540 | +38.4% | 0.19% | +23.0% |
| Q1 2023 | $276,900 | +10.5% | 20,618 | +1.8% | 0.15% | +16.0% |
| Q4 2022 | $250,505 | -21.2% | 20,251 | -5.3% | 0.13% | -6.4% |
| Q3 2021 | $318,000 | -31.8% | 21,387 | -8.4% | 0.14% | -27.1% |
| Q2 2021 | $466,000 | +4.3% | 23,353 | +20.5% | 0.19% | +1.6% |
| Q1 2021 | $447,000 | -4.1% | 19,375 | +2.8% | 0.19% | -2.1% |
| Q4 2020 | $466,000 | +44.7% | 18,849 | +142.5% | 0.19% | +14.2% |
| Q3 2020 | $322,000 | -5.6% | 7,774 | +9.2% | 0.17% | +5.0% |
| Q2 2020 | $341,000 | +4.9% | 7,119 | +38.1% | 0.16% | +20.1% |
| Q1 2020 | $325,000 | -53.1% | 5,156 | -7.8% | 0.13% | +18.6% |
| Q4 2019 | $693,000 | +19.9% | 5,591 | -35.8% | 0.11% | -2.6% |
| Q3 2019 | $578,000 | -28.6% | 8,711 | -14.4% | 0.12% | -32.2% |
| Q2 2019 | $810,000 | +1.5% | 10,180 | +42.6% | 0.17% | -89.9% |
| Q1 2019 | $798,000 | +42.5% | 7,138 | +28.4% | 1.70% | +1668.8% |
| Q4 2018 | $560,000 | -53.9% | 5,560 | -42.2% | 0.10% | -23.8% |
| Q3 2018 | $1,215,000 | +61.4% | 9,618 | +7.2% | 0.13% | -81.1% |
| Q2 2018 | $753,000 | -16.6% | 8,970 | -38.9% | 0.67% | -14.9% |
| Q1 2018 | $903,000 | -0.6% | 14,681 | -5.5% | 0.78% | -31.3% |
| Q4 2017 | $908,000 | +84.2% | 15,542 | +82.8% | 1.14% | +1625.8% |
| Q3 2017 | $493,000 | -52.1% | 8,501 | 0.0% | 0.07% | -57.1% |
| Q2 2017 | $1,029,000 | -8.4% | 8,501 | -14.3% | 0.15% | -23.0% |
| Q1 2017 | $1,123,000 | +15.2% | 9,925 | +10.6% | 0.20% | -31.3% |
| Q4 2016 | $975,000 | +35.2% | 8,971 | +104.9% | 0.29% | -16.6% |
| Q3 2016 | $721,000 | +32.1% | 4,378 | +14.4% | 0.35% | -13.8% |
| Q2 2016 | $546,000 | +177.2% | 3,826 | +149.3% | 0.40% | +49.4% |
| Q1 2016 | $197,000 | – | 1,535 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |